Acquired drug resistance to even the most effective anti-cancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified, the underlying molecular mechanisms shaping tumor evolution during treatment are incompletely understood. The extent to which therapy actively drives tumor evolution by promoting mutagenic processes or simply provides the selective pressure necessary for the outgrowth of drug-resistant clones remains an open question. Here, we report that lung cancer targeted therapies commonly used in the clinic induce the expression of cytidine deaminase APOBEC3A (A3A), leading to sustained mutagenesis in drug-tolerant cancer cells persisting during therapy. Induction of A3A facilitated the formation of double-strand DNA breaks (DSBs) in cycling drug-treated cells, and fully resistant clones that evolved from drug-tolerant intermediates exhibited an elevated burden of chromosomal aberrations such as copy number..... READ ARTICLE
BioRxIV DOI:10.1101/2021.01.20.426852
Authors: Hideko Isozaki, Ammal Abbasi, Naveed Nikpour, Adam Langenbucher, Wenjia Su,
Marcello Stanzione, Heidie Frisco Cabanos, Faria M. Siddiqui, Nicole Phan, Pégah Jalili,
Sunwoo Oh, Daria Timonina, Samantha Bilton, Maria Gomez-Caraballo, Hannah L.
Archibald, Varuna Nangia, Kristin Dionne, Amanda Riley, Matthew Lawlor, Mandeep Kaur Banwait, Rosemary G. Cobb, Lee Zou, Nicholas J. Dyson, Christopher J. Ott, Cyril
Benes, Gad Getz, Chang S. Chan, Alice T. Shaw, Jessica J. Lin, Lecia V. Sequist,
Zofia Piotrowska, Jeffrey A. Engelman, Jake June-Koo Lee, Yosef Maruvka, Rémi
Buisson, Michael S. Lawrence, Aaron N. Hata